Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Research · 2024-01 · 7
DOI: 10.34133/research.0370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 18.06.2024. Verfasst von Xiaonan Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sinovac Biotech Ltd., Beijing, PR China. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, Distinguished Young Scholars of the National Natural Science Foundation of China, Major Program of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Messenger RNA (mRNA) has emerged as an innovative therapeutic modality, offering promising avenues for the prevention and treatment of a variety of diseases. The tremendous success of mRNA vaccines in effectively combatting coronavirus disease 2019 (COVID-19) evidences the unlimited medical and therapeutic potential of mRNA technology. Overcoming challenges related to mRNA stability, immunogenicity, and precision targeting has been made possible by recent advancements in lipid nanoparticles (LNPs). This review summarizes state-of-the-art LNP-mRNA-based therapeutics, including their structure, material compositions, design guidelines, and screening principles. Additionally, we highlight current preclinical and clinical trends in LNP-mRNA therapeutics in a broad range of treatments in ophthalmological conditions, cancer immunotherapy, gene editing, and rare-disease medicine. Particular attention is given to the translation and evolution of LNP-mRNA vaccines into a broader spectrum of therapeutics. We explore concerns in the aspects of inadequate extrahepatic targeting efficacy, elevated doses, safety concerns, and challenges of large-scale production procedures. This discussion may offer insights and perspectives on near- and long-term clinical development prospects for LNP-mRNA therapeutics.
Autor:innen und Institutionen
- Sinovac Biotech Ltd., Beijing, PR China.
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China.
- School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing, PR China.
ORCID-Profile: Xiaonan Huang, Yufei Xia
Förderung
- National Key Research and Development Program of China
- Distinguished Young Scholars of the National Natural Science Foundation of China
- Major Program of the National Natural Science Foundation of China
- Key Project of the National Natural Science Foundation of China
- CAS Project for Young Scientists in Basic Research
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
Zitieren
APA
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024). Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies. Research, 7. https://doi.org/10.34133/research.0370
Vancouver
Huang X, Ma Y, Ma G, Xia Y. Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies. Research. 2024;7. doi:10.34133/research.0370
BibTeX
@article{Huang2024,
author = {Huang, Xiaonan and Ma, Yishan and Ma, Guanghui and Xia, Yufei},
title = {Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies},
journal = {Research},
year = {2024},
volume = {7},
doi = {10.34133/research.0370}
}
EUVIMED